Home » Our work » Medicines Management » Policies, guidelines & legacy documents » Medicines Management Commissioning Policies
Medicines Management Commissioning Policies
- Drugs used on Primary Care for the treatment of erectile dysfunction (ED)
- Safety pen needles and safety lancet devices - Commissioning Statement-NHS STW V3
- Individual Funding Request Policy (IFR)
- Individual Funding Request application form
- Funding for Experimental and Unproven Treatments
- On-going access to treatment following a trial of treatment which has not been sanctioned by NHS STW
- On-going access to treatment following the completion of a trial explicitly funded by NHS STW
- On-going access to treatment following the completion of industry sponsored clinical trials or funding.
- On-going access to treatment following the completion of non-commercially funded clinical trials
- Ethical framework for priority setting and resource allocation allocation
- Policy for Joint Working with the Pharmaceutical Industry
- NHS Shropshire Telford & Wrekin Liothyronine Policy V2
- NHS Shropshire Telford & Wrekin Primary Care Rebates Sept 23
- Continuous Glucose Monitoring (CGM) for Type 1 Diabetes in Adults and Pregnant women with Type 1 or Type 2 Diabetes on insulin therapy
- Continuous Glucose Monitoring (CGM) for Type 1 Diabetes in Children and Young People aged up to 19 years
- Continuous Subcutaneous Insulin Infusion (CSII) without CGM in adults and children with Type 1 Diabetes
- The-use-of-Flash-Glucose-Monitoring-systems-in-eligible-diabetic-patients (1)
- STW Gluten Free Statement
- Botulinum Toxin Policy
- Non-Medical Prescribing Policy Feb 2022
- Insulin degludec for Type 1 and restricted use in Type 2 diabetes
- Bath and Shower preparations in Primary Care Policy V2